医学
造血干细胞移植
多发性硬化
移植
临床试验
免疫系统
免疫学
重症监护医学
内科学
作者
Sue‐Ann Ng,Keith M. Sullivan
出处
期刊:Current Opinion in Hematology
[Ovid Technologies (Wolters Kluwer)]
日期:2019-09-04
卷期号:26 (6): 392-398
被引量:14
标识
DOI:10.1097/moh.0000000000000531
摘要
Autologous hematopoietic stem cell transplantation (HSCT) is a promising therapeutic modality for severe autoimmune diseases. In this review, we will outline the immunological mechanisms and the clinical evidence and experiences for therapeutic HSCT in autoimmune diseases, with particular focus on systemic sclerosis and multiple sclerosis.Approximately 3000 patients with autoimmune diseases worldwide have been treated with HSCT. HSCT in systemic sclerosis has been shown in three randomized controlled trials to be associated with significant long-term event-free survival despite some transplant-related mortality in the first year. A recent controlled trial in multiple sclerosis has also show benefit with transplant.The aim of HSCT is to 'reset' one's immune system into a naïve and self-tolerant state through immune depletion and regulation. HSCT requires careful patient selection, close collaboration between physicians and expertise of transplant team to ensure optimal outcome.
科研通智能强力驱动
Strongly Powered by AbleSci AI